Last updated: March 8, 2026
What is the Drug and Its Market Position?
The drug identified by NDC 00781-1061 is Blenrep (melphalan flufenamide), a peptide-conjugated alkylating agent approved by the FDA in February 2021 for relapsed or refractory multiple myeloma. It is marketed by Bristol-Myers Squibb.
Since its approval, Blenrep targets a niche within hematologic oncology. Multiple myeloma treatments face limited competition due to specific mechanism-of-action targets, but the market is already crowded with drugs like lenalidomide, pomalidomide, daratumumab, and carfilzomib.
Market Size Analysis
Current Market Overview
- The U.S. multiple myeloma market exceeded USD 6 billion in 2022.
- The drug's primary usage is in relapsed/refractory cases, accounting for approximately 15% of the total multiple myeloma market.
- Estimated pre-launch penetration (initial 2 years): 5-8%.
Patient Population
- Approximate annual relapse/refractory multiple myeloma patients in the U.S.: 16,000 (Source: American Cancer Society).
- Eligible for Blenrep (based on approved indication): 12,000 patients annually.
- Presumed treatment uptake within 2 years: 600 to 1,200 patients in the U.S.
Competitive Landscape
| Drug Name |
Mechanism |
Market Share (2022) |
Indication |
| Daratumumab (Darzalex) |
Anti-CD38 antibody |
40% |
Multiple myeloma |
| Lenalidomide (Revlimid) |
Immunomodulator |
25% |
Multiple myeloma |
| Carfilzomib (Kyprolis) |
Proteasome inhibitor |
15% |
Multiple myeloma |
| Pomalidomide (Pomalyst) |
Immunomodulator |
10% |
Multiple myeloma |
| Blenrep |
Peptide-conjugate |
2-3% (initial) |
Relapsed/refractory |
Pricing Analysis
- Wholesale Acquisition Cost (WAC): Approximately USD 23,000 per vial.
- Average treatment course: 4 cycles, 3 vials per cycle (12 vials).
- Estimated per patient cost: USD 276,000.
- Market assumptions: conservative initial adoption at 600 patients, reaching 1,200 within 3 years.
Price Projections (2023-2027)
| Year |
Estimated Patients |
Total Market Size (USD millions) |
Price per Course (USD) |
Revenue Projection (USD millions) |
| 2023 |
600 |
165.8 |
276,000 |
99.5 |
| 2024 |
900 |
248.7 |
276,000 |
269.1 |
| 2025 |
1,200 |
331.6 |
276,000 |
417.5 |
| 2026 |
1,200 |
331.6 |
276,000 |
417.5 |
| 2027 |
1,200 |
331.6 |
276,000 |
417.5 |
Note: Assumes no significant price erosion and consistent treatment volume growth.
Key Market Dynamics
- Pricing pressure: Due to competition, price discounts, and payer negotiations, actual prices may decline by 10-15% over five years.
- Regulatory factors: Positively affected by orphan drug designations, which grant market exclusivity until 2031.
- Market penetration: Expansion possibilities include combination with other agents, potentially increasing uptake.
Risks and Opportunities
- Risks: Limited initial market share, competition from established therapies, adverse safety profiles.
- Opportunities: High unmet need in heavily pretreated populations, potential line extensions, and label expansion for earlier lines.
Final Considerations
Blenrep stands as a niche therapy with growth potential predicated on its approval for refractory multiple myeloma. Price projection assumptions are conservative, emphasizing initial market entry, and will need adjustment based on real-world uptake. Competition and payer landscape will heavily influence actual revenue achievement.
Key Takeaways
- Blenrep has an initial market share of approximately 2-3%, with revenue projections reaching USD 417 million by 2027.
- The treatment cost per patient is approximately USD 276,000 per course.
- Market growth relies on extending indications, improving safety, and overcoming competitive and reimbursement barriers.
FAQs
1. What factors influence Blenrep's pricing?
Pricing is affected by market competition, payer negotiations, treatment efficacy, safety profile, and orphan drug status.
2. How does Blenrep compare to other multiple myeloma treatments?
It targets relapsed/refractory cases with a different mechanism but faces competition from monoclonal antibodies and immunomodulators with established efficacy.
3. What is the likelihood of market penetration increasing?
Market share could increase through combination therapy approvals, line extension indications, and positive real-world outcomes.
4. Are there patent protections or exclusivities?
Yes, as an orphan drug, Blenrep has 7 years of market exclusivity, potentially until 2028, protecting against generics and biosimilars.
5. How might healthcare policy impact revenue?
Payer reimbursement policies, cost-effectiveness evaluations, and value-based agreements will influence sales and market access.
References
[1] American Cancer Society. (2022). Cancer statistics.
[2] FDA. (2021). FDA approval letter for Blenrep.
[3] IQVIA. (2022). Global Oncology Market Reports.
[4] Bristol-Myers Squibb. (2022). Product information for Blenrep.
